Nachrichten zur Agios Pharmaceuticals Inc. Aktie

Insiderhandel: Chief Medical Officer verkauft Aktien von Agios Pharmaceuticals im Wert von 793.582$

Bowden, Christopher - Vorstand - Tag der Transaktion: 2021-04-20...…

Insiderhandel: Chief Medical Officer verkauft Aktien von Agios Pharmaceuticals im Wert von 177.055$

Bowden, Christopher - Vorstand - Tag der Transaktion: 2021-04-19...…

Agios A Buy For Rare Disease Focus, Stock Buyback

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AGIOS PHARMACEUTICALS, INC.: 8-K Report

8-K...…

AGIOS PHARMACEUTICALS, INC.: 8-K Report

8-K...…

Agios to repurchase $345 million stock from Bristol-Myers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Announces Closing of Oncology Business Sale to Servier

Agios Receives $1.8 Billion in Upfront Cash to Focus on Accelerating and Expanding its Genetically Defined Disease Portfolio...…

AGIOS PHARMACEUTICALS, INC.: 8-K Report

8-K...…

Agios shareholders approve oncology business sale to Servier Pharmaceuticals

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Shareholders Approve Sale of Oncology Business to Servier

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field…

AGIOS PHARMACEUTICALS, INC.: 8-K Report

8-K...…

Agios cut to neutral at JPM citing valuation and lack of notable catalysts

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios submits TIBSOVO marketing application to FDA

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Pharmaceuticals Inc (AGIO) Q4 2020 Earnings Call Transcript

AGIO earnings call for the period ending December 31, 2020....…

Agios Pharmaceuticals, Inc. (AGIO) CEO Dr. Jackie Fouse on Q4 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AGIOS PHARMACEUTICALS, INC.: 10-K Report

10-K...…

AGIOS PHARMACEUTICALS, INC.: 8-K Report

8-K...…

Agios Reports Fourth Quarter and Full Year 2020 Financial Results

– Strong Commercial Execution for Second Full Year of TIBSOVO® with Fourth Quarter Net Revenue of $39.1M and $121.1M for Full Year 2020 –...…

Agios Pharmaceuticals Q4 2020 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios to Present at March Investor Conferences

CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of…

Agios: Back To The Lab

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AGIOS PHARMACEUTICALS, INC.: 8-K Report

8-K...…

AGIOS PHARMACEUTICALS, INC.: 8-K Report

8-K...…

Agios reports final data analysis in late-stage trial for rare cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

– Supplemental New Drug Application Planned for Submission in Q1 2021 – – Supplemental New Drug Application Planned for Submission…

Agios Pharmaceuticals (AGIO) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios highlights 2021 milestones, sees filing for sickle cell drug U.S. approval in Q2

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AGIOS PHARMACEUTICALS, INC.: 8-K Report

8-K...…

Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation

– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency…

Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of…

Agios Pharmaceuticals: A Pivot From Cancer Metabolism To Rare Diseases

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Are Options Traders Betting on a Big Move in Agios (AGIO) Stock?

Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately....…

Agios (AGIO) to Sell Oncology Drugs to Servier for $2B, Stock Up

Agios (AGIO) sells its oncology business unit to French company Servier for around $2 billion. The company plans to solely…

AGIOS PHARMACEUTICALS, INC.: 8-K Report

8-K...…

Agios Stock Is Soaring Because of a Major Sale

Agios stock is soaring in Monday trading after announcing the sale of its cancer products. The company will focus on…

Why Agios Pharmaceuticals Stock Is Soaring Today

Investors applauded the companys planned sale of its oncology portfolio....…

Thinking about buying stock in Agios Pharmaceuticals, Clovis Oncology, Aqua Metals, Cocrystal Pharma, or Luminar Technologies?

NEW YORK , Dec. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGIO,…

Agios Soars on Plan to Sell Cancer Drugs, Return $1.2B to Holders

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agios shares jump 20% after announcing plans to sell cancer portfolio

Shares of Agios Pharmaceuticals Inc. soared 20.6% in premarket trading on Monday after the company said it is selling…

Agios to Sell Its Cancer Portfolio to Servier for $1.8 Billion

Agios to Sell Its Cancer Portfolio to Servier for $1.8 Billion...…

Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties

– Agios to Dedicate All Resources to Advancing Mitapivat as a Potential Treatment for Three Initial Hemolytic Anemias and Building…

Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting

Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET Company to Host…